Aspira Women’s Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024
14 Dezembro 2023 - 10:00AM
Aspira Women’s Health Inc. (“Aspira” or “the
Company”) (Nasdaq: AWH), a bio-analytical based women’s health
company focused on the development of gynecologic disease
diagnostic tools, today announced that management will be
available for partnering and institutional one-on-one meetings in
San Francisco, during JP Morgan’s Healthcare Conference Week 2024.
Nicole Sandford, President and Chief Executive Officer, in addition
to Torsten Hombeck, Ph.D., Chief Financial Officer from the
management team will be in attendance at the following corporate
access and partnering events:
Upcoming Corporate Access Event
Participation
12th Annual LifeSci
Partners Corporate Access Event 2024 |
Date: |
January 8-9, 2024 |
Location: |
Beacon Grand Hotel (formerly the Sir Francis Drake Hotel) |
For partnering and institutional one-on-one
meeting requests please register via the following link:
https://lifescievents.com/event/cae2024/
H.C. Wainwright & Co. Hosted Investor
Meetings |
Date: |
January 10, 2024 |
Location: |
Beacon Grand Hotel (formerly the Sir Francis Drake Hotel) |
For partnering and institutional one-on-one
meeting requests please contact your representative at H.C.
Wainwright & Co.
About Aspira Women’s Health Inc.Aspira
Women’s Health Inc. is transforming women’s gynecological health
with the discovery, development, and commercialization of
innovative testing options for women of all races and ethnicities,
starting with ovarian cancer. Our ovarian cancer risk
assessment portfolio is marketed to healthcare providers as
OvaSuiteSM, which includes OvaWatchSM, a non-invasive, blood-based
test intended for use in the initial clinical assessment of ovarian
cancer risk in women with benign or indeterminate adnexal masses
for which surgical intervention may be either premature or
unnecessary. With a negative predictive value (NPV) of 99%,
OvaWatch allows physicians to confidently rule out ovarian cancer
malignancy and choose the appropriate clinical management for the
right patient at the right time. Ova1Plus® combines our
FDA-cleared products, Ova1® and Overa®, to detect risk of
ovarian malignancy in women with adnexal masses planned for
surgery.
EndoCheckSM, Aspira’s first-of-its-kind
non-invasive diagnostic test for endometriosis, is currently in
development. Visit our website for more information
at www.aspirawh.com.
Forward-Looking StatementsThis press release
contains forward-looking statements, as defined in the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements generally are accompanied by words such as “will,”
“plan,” “intend,” “potential,” “expect,” “could,” or the negative
of these words and similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. These forward-looking statements include, but are not
limited to, statements regarding the development of diagnostic
tools, ability to offer patients and physicians a range of cost
effective, non-invasive alternatives for diagnosing endometriosis,
the verification of tests in other forms of endometriosis,
validation and timing of the launch of EndoCheck, the impact on
EndoCheck’s addressable market, and ability to drive long-term
shareholder value . These statements are based on various
assumptions, whether or not identified in this press release, and
on the current expectations of the management of Aspira and are not
predictions of actual performance. These forward-looking statements
are provided for illustrative purposes only and are not intended to
serve as, and must not be relied on as a guarantee, an assurance, a
prediction, or a definitive statement of fact or probability.
Actual events and circumstances are difficult or impossible to
predict and will differ from assumptions. Many actual events and
circumstances are beyond the control of Aspira. These
forward-looking statements are subject to a number of risks and
uncertainties, including but not limited to: our ability to
continue as a going concern; our ability to comply with Nasdaq’s
continued listing requirements; impacts resulting from potential
changes to coverage of Ova1 through our Medicare Administrative
Carrier for Ova1; anticipated use of capital and its effects; our
ability to increase the volume of our product sales; failures by
third-party payers to reimburse for our products and services or
changes to reimbursement rates; our ability to continue developing
existing technologies and to develop, protect and promote our
proprietary technologies; plans to develop and perform laboratory
developed tests; our ability to comply with Food and Drug
Administration (“FDA”) regulations that relate to our products and
to obtain any FDA clearance or approval required to develop and
commercialize medical devices; our ability to develop and
commercialize additional diagnostic products and achieve market
acceptance with respect to these products; our ability to compete
successfully; our ability to obtain any regulatory approval
required for our future diagnostic products; or our suppliers’
ability to comply with FDA requirements for production, marketing
and post-market monitoring of our products; our ability to maintain
sufficient or acceptable supplies of immunoassay kits from our
suppliers; in the event that we succeed in commercializing our
products outside the United States, the political, economic and
other conditions affecting other countries; changes in healthcare
policy; our ability to comply with the additional laws and
regulations that apply to us in connection with the operation of
Aspira Labs; our ability to use our net operating loss
carryforwards; our ability to use intellectual property; our
ability to successfully defend our proprietary technology against
third parties; our ability to obtain licenses in the event a third
party successfully asserts proprietary rights; the liquidity and
trading volume of our common stock; the concentration of ownership
of our common stock; our ability to retain key employees; our
ability to secure additional capital on acceptable terms to execute
our business plan; business interruptions; the effectiveness and
availability of our information systems; our ability to integrate
and achieve anticipated results from any acquisitions or strategic
alliances; future litigation against us, including infringement of
intellectual property and product liability exposure; the impact of
additional costs that may be required to make further improvements
to our laboratory operations; and all other factors discussed in
Aspira’s Annual Report on Form 10-K for the year ended December 31,
2022 and Aspira’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2023 under the heading “Risk Factors,” and
other documents Aspira has filed, or will file, with the Securities
and Exchange Commission. If any of these risks materialize or our
assumptions prove incorrect, actual results could differ materially
from the results implied by these forward-looking statements. There
may be additional risks that Aspira presently does not know, or
that Aspira currently believes are immaterial, that could also
cause actual results to differ from those contained in the
forward-looking statements. In addition, forward-looking statements
reflect Aspira’s expectations, plans, or forecasts of future events
and views as of the date of this press release. Aspira anticipates
that subsequent events and developments will cause its assessments
to change. However, while Aspira may elect to update these
forward-looking statements at some point in the future, Aspira
specifically disclaims any obligation to do so, except as required
by law. These forward-looking statements should not be relied upon
as representing Aspira’s assessments of any date after the date of
this press release. Accordingly, undue reliance should not be
placed upon the forward-looking statements.
Investor Relations Contact:
Jamie SullivanDirector of Corporate CommunicationsAspira Women’s
HealthJsullivan@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Aspira Womans Health (NASDAQ:AWH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024